Catalog No.
DHJ57401
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
DPEP3, Dipeptidase 3
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9H4B8
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
170, CAS: 339177-26-3
Clone ID
Pintumomab
MUC1 immunotherapy, PMID: 20635898
Monoclonal and bispecific antibodies as novel therapeutics, PMID: 16648969
[Immunotherapy--perspectives in therapy of ovarian carcinomas], PMID: 15587893
Biologic and immunologic therapies for ovarian cancer, PMID: 12743131
Technology evaluation: R-1549, Antisoma/Roche, PMID: 14601527
Consolidation for ovarian cancer in remission, PMID: 16446325
Xanthogranulomatous reaction to a ruptured galactocele, PMID: 20202042
Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1, PMID: 16265351
Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC), PMID: 18684557
MUC-1 mucin in normal human salivary glands detected by HMFG-1 and HMFG-2 monoclonal antibodies, PMID: 18321359
Development of ELISAs for quantification of HMFG1-specific human anti-mouse IgG and IgM antibodies, PMID: 17922458
Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer, PMID: 18661524
Reversal of glandular polarity in the lymphovascular compartment of breast cancer, PMID: 15452174
Human anti-mouse IgM and IgG responses in ovarian cancer patients after radioimmunotherapy with 90Y-muHMFG1, PMID: 19035301
High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC), PMID: 17692456
SMART? Time will tell, PMID: 12442760
Concurrent radiotherapy and tumor targeting with 111In-HMFG1-F(ab')2 in patients with MUC1-positive non-small cell lung cancer, PMID: 16334158
A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer, PMID: 15127236
Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme, PMID: 15150594
The MUC1 HMFG1 glycoform is a precursor to the 214D4 glycoform in the human uterine epithelial cell line, HES, PMID: 17989354
Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: Effect of the radionuclide, PMID: 14675343
Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8, PMID: 23275306
Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin, PMID: 11877758
Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival, PMID: 17354223
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission, PMID: 16446329
Gastric metaplasia and small bowel ulcerogenesis in a case of ulcerative jejunitis not related to celiac disease, PMID: 15494871
Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer, PMID: 17803445
For research use only. Not for human or drug use.
